Uncover key drivers, emerging technologies, and competitive movements shaping the cancer clinical decision tools market from 2026–2035 with trusted insights from The Business Research Company
What level of growth is expected in the Cancer Clinical Decision Tools Market between 2026 and 2030?
The market for cancer clinical decision tools has shown substantial expansion lately. Forecasts indicate it will expand from $0.55 billion in 2025 to $0.6 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.0%. This historical increase can be ascribed to several factors, including an increase in cancer incidence rates, the growing workload faced by primary care physicians, the scarcity of early diagnostic instruments in primary care settings, a greater focus on the accuracy of referrals, and the development of hospital and clinic infrastructure.
The cancer clinical decision tools market size is expected to experience rapid growth over the next few years, projected to reach $0.88 billion by 2030 at a compound annual growth rate (CAGR) of 10.2%. This anticipated expansion can be attributed to several factors, including the advancement of AI-driven decision tools, the integration of genomic and risk profiling data, the expansion of digital health platforms, increasing government screening initiatives, and the growing adoption of evidence-based oncology guidelines. Major trends foreseen during this period encompass the increasing adoption of clinical decision support tools in oncology, a rising focus on early cancer detection and risk stratification, the growing use of symptom checkers and risk calculators by GPs, the expansion of guideline-based referral and decision frameworks, and the integration of cancer decision tools into primary care workflows.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3463&type=smp
Which Drivers Are Expected To Impact The Cancer Clinical Decision Tools Market During The Forecast Period?
The increasing occurrence of cancer is projected to stimulate the growth of the cancer clinical decision tools market moving forward. Cancer incidence defines the count of new cancer diagnoses made within a specific population over a particular period, indicating the frequency with which the disease manifests. This upward trend in cancer incidence is due to elevated exposure to risk factors, including unhealthy lifestyles, which can gradually result in genetic mutations and abnormal cell proliferation. Cancer clinical decision tools are instrumental in more effectively tracking, predicting, and managing cancer cases, facilitating early detection and prompt intervention capable of impacting observed cancer incidence trends. For instance, in October 2025, according to the NHS England, a UK-based publicly funded healthcare system, 354,820 new cancer diagnoses were recorded in 2023, representing an increase of 8,605 compared to 2022. Consequently, the worldwide rise in cancer incidence rates will boost the demand for the cancer clinical decision tools market.
How Is The Cancer Clinical Decision Tools Market Divided Into Segments?
The cancer clinical decision tools market covered in this report is segmented –
1) By Type: Risk Assessment Tool(RAT), Qcancer
2) By End-User: Hospital, Clinics
Subsegments:
1) By Risk Assessment Tool (RAT): Family History Assessment, Genetic Testing and Counseling, Lifestyle and Environmental Risk Factors Evaluation
2) By Qcancer: Symptom Checker, Risk Calculator, Guideline-Based Recommendations
What Long-Term Trends Are Expected To Shape The Future Of The Cancer Clinical Decision Tools Market?
Leading companies within the cancer clinical decision tools market are increasingly deploying AI-powered prognostic decision support systems. This adoption addresses the growing demand for personalized, data-driven oncology care, which is driven by rising cancer incidence, the necessity for improved risk stratification, and the imperative to optimize treatment pathways. These AI prognostic systems utilize deep-learning models to analyze diverse multimodal data, including imaging, electronic health records, and clinical biomarkers, allowing for significantly more precise predictions of outcomes such as survival, recurrence risk, or treatment response compared to conventional rule-based tools. As an illustration, in February 2025, Onc.AI, a US-based health-tech company, announced that its Serial CTRS (Cancer Treatment Risk Stratification) tool received FDA Breakthrough Device Designation. This AI tool classifies non–small cell lung cancer (NSCLC) patients into high- and low-risk mortality categories by analyzing diagnostic imaging scans via a deep-learning algorithm, thereby assisting oncologists in making more informed decisions regarding therapy intensity and follow-up. The Serial CTRS’s capacity to predict long-term survival outcomes facilitates enhanced patient stratification, more customized treatment planning, and optimized resource allocation, signifying a substantial advancement over conventional prognostic models that depend on limited clinical parameters.
Which Key Market Players Are Investing In Expansion And Innovation Within The Cancer Clinical Decision Tools Market?
Major companies operating in the cancer clinical decision tools market are McKesson Corporation, Philips Healthcare, Siemens Healthineers AG, Elsevier B.V., National Decision Support Company, Cerner Corporation, GE Healthcare, Allscripts Healthcare Solutions Inc., Epic Systems Corporation, RaySearch Laboratories AB, Elekta AB, Varian Medical Systems Inc., Accuray Incorporated, F. Hoffmann-La Roche Ltd., Flatiron Health Inc., Tempus Labs Inc., NantHealth Inc., Syapse Inc., Inspirata Inc., Prognos Health Inc., Deep 6 AI Inc., PathAI Inc.
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Which Regions Are Poised For Strategic Growth In The Cancer Clinical Decision Tools Market?
North America was the largest region in the cancer clinical decision tools market in 2025. The regions covered in the cancer clinical decision tools market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Cancer Clinical Decision Tools Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=3463&type=smp
Browse Through More Reports Similar to the Global Cancer Clinical Decision Tools Market 2026, By The Business Research Company
Polymerase Chain Reactions Devices Reagents And Uses Market Report 2026
Cardiovascular Monitoring And Diagnostic Devices And Equipment Market Report 2026
Veterinary Diagnostic Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model